What is Arine?
Arine operates at the intersection of artificial intelligence and clinical pharmacology. The company provides a sophisticated medication optimization platform designed to ensure that patients receive the most effective therapeutic regimens. By integrating deep clinical expertise with real-time data analytics, Arine delivers personalized, actionable recommendations that enhance medication safety and adherence. This approach is particularly valuable for health plans and provider organizations managing complex patient populations, where medication errors and non-adherence represent significant cost drivers and health risks. Through its technology, Arine effectively bridges the gap between complex clinical guidelines and individual patient needs, driving measurable improvements in care quality.
How much funding has Arine raised?
Arine has raised a total of $70M across 3 funding rounds:
Series A
$11M
Series B
$29M
Series C
$30M
Series A (2021): $11M with participation from Katalyst Ventures, Magellan Health, 111° West Capital Partners, and Scan Group
Series B (2022): $29M led by 111° West Capital, Super Capital Group, New Leaf Venture Partners, MBX Capital, and Katalyst Ventures
Series C (2025): $30M supported by Town Hall Ventures and Kaiser Permanente
Key Investors in Arine
Town Hall Ventures
Town Hall Ventures partners with founders addressing long-standing healthcare challenges for underserved communities, focusing on innovative solutions in areas like school-based mental health and rural healthcare.
Kaiser Permanente
Kaiser Permanente is a leading not-for-profit healthcare organization providing integrated medical services through its extensive network of hospitals, clinics, and health plans.
New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm focused on funding innovative companies in the healthcare sector, supporting transformative technologies that improve patient care.
What's next for Arine?
With the successful closure of this latest financing, Arine is well-positioned to deepen its technological moat and expand its footprint within the enterprise healthcare sector. The strategic focus will likely center on enhancing the platform's predictive modeling capabilities and broadening its integration with existing electronic health record systems. As the healthcare industry continues to shift toward value-based care models, Arine's ability to demonstrate clear ROI through improved patient outcomes and reduced costs will be instrumental in securing further market share. The company is expected to utilize this capital to scale its operational infrastructure and support the growing demand for data-driven medication management solutions.
See full Arine company page
